PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
Irisin is related to insulin resistance and metabolic disorders. The physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α (PPAR-α). We investigated the effect of fenofibrate, a PPAR-α agonist, on serum irisin in type 2 diabetes patients with hyper...
Saved in:
Main Authors: | Xiaomeng Feng, Xia Gao, Yumei Jia, Heng Zhang, Qingrong Pan, Zhi Yao, Ning Yang, Jia Liu, Yuan Xu, Guang Wang, Xinchun Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2015/924131 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
by: Wen Bao, et al.
Published: (2021-01-01) -
Role of PPARα and Its Agonist in Renal Diseases
by: Ching-Feng Cheng, et al.
Published: (2010-01-01) -
PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
by: Neerupma Silswal, et al.
Published: (2012-01-01) -
Beneficial Effect of Fenofibrate in Combination with Silymarin on Parameters of Hereditary Hypertriglyceridemia-Induced Disorders in an Animal Model of Metabolic Syndrome
by: Jan Soukop, et al.
Published: (2025-01-01) -
2D-QSAR Analysis of Oxadiazole Substituted α-Isopropoxy phenylpropionic Acids as PPAR-α & PPAR-λ Agonists
by: Soni L. K., et al.
Published: (2004-01-01)